Characterization of an orf virus isolate from an outbreak in Heilongjiang province, China.

Contagious ecthyma, caused by orf virus (ORFV), is an epitheliotrophic contagious disease with zoonotic implications that mainly affects sheep, goats, wild ruminants, and humans. Recently, a novel ORFV strain, OV/HLJ/04, was successfully isolated from the skin and mucosal lesions of a goat with severe clinical sore mouth symptoms in Heilongjiang province of China. The OV/HLJ/04 isolate was characterized by electron microscopy, serological tests, and experimental reproduction of disease. The purified virions exhibited a typical ovoid shape when observed by electron microscopy. Moreover, experimental reproduction of disease showed that a lamb developed typical clinical signs of contagious ecthyma, such as severe vascular proliferation, when inoculated with the virus. Subsequently, amplification of ORFV011 (B2L) gene fragments of viral DNA by polymerase chain reaction (PCR) and gene sequencing were performed. Phylogenetic analysis of the B2L protein gene revealed that this strain clusters with ORFV strains from epidemic-stricken areas worldwide, including recent mainland China isolates. Analysis using ClustalW MegAlign in DNAStar indicated that OV/HLJ/04 (GenBank: KU523790.1) was genetically closely related to the isolates Gansu (JQ904789), with 99.7% identity; NZ2 (DQ184476), with 97.4% identity; and Xinjiang (KF666560), with 90.6% identity. These results may provide insights into the genotype of the etiological agent responsible for the orf outbreak in Heilongjiang Province.

PEI-PLGA nanoparticles significantly enhanced the immunogenicity of IsdB137-361 proteins from Staphylococcus aureus.

INTRODUCTION: Staphylococcus aureus seriously threatens human and animal health. IsdB137-361 of the iron surface determinant B protein (IsdB) from S. aureus exhibits the strong immunogenicity, but its immunoprotective effect is still to be further promoted. Because PEI-PLGA nanoparticles are generated by PEI conjugate with PLGA to develop great potential as a novel immune adjuvant, the immunogenicity of IsdB137-361 is likely be strengthened by PEI-PLGA. METHODS: Here, PEI-PLGA nanoparticles containing IsdB137-361 proteins were prepared by optimizing the entrapment efficiency. Mice were immunized with IsdB137-361 -PEI-PLGA nanoparticles to assess their anti-S. aureus effects. The level of IFN-γ, IL-4, IL-17, and IL-10 cytokines from spleen lymphocytes in mice and generation of the antibodies against IsdB137-361 in serum was assessed by ELISA, the protective immune response was appraised by S. aureus challenge. RESULTS: IsdB137-361 proteins loaded by PEI-PLGA were able to stimulate effectively the proliferation of spleen lymphocytes and increase the secretion of IFN-γ, IL-4, IL-17, and IL-10 cytokine from spleen lymphocytes, and significantly enhance generation of the antibodies against IsdB137-361 in serum, reduce the level of bacterial load in liver, spleen and kidney, and greatly improve the survival rate of mice after challenge. CONCLUSION: These data showed that PEI-PLGA nanoparticles can significantly enhance the immunogenicity of IsdB137-361 proteins, and provide an important reference for the development of novel immune adjuvant.

Immune responses to the oral administration of recombinant Bacillus subtilis expressing multi-epitopes of foot-and-mouth disease virus and a cholera toxin B subunit.

Bacillus subtilis has been engineered successfully to express heterologous antigens for use as a vaccine vehicle that can elicit mucosal and systemic immunity response. In this study, a recombinant B. subtilis expressing the B subunit of cholera toxin (CT-B) and an epitope box constituted with antigen sites from foot-and-mouth disease virus (FMDV) type Asia 1 was constructed and named 1A751/CTB-TEpiAs. Its capability to induce mucosal, humoral, and cellular responses in mice and guinea pigs was evaluated after oral administration with vegetative cells of 1A751/CTB-TEpiAs. In addition, its capability to protect guinea pigs against homologous virus challenge was examined. All animals were given booster vaccination at day 21 after initial inoculation and guinea pigs were challenged 3 weeks after booster vaccination. The control groups were inoculated with a commercial vaccine or administered orally with 1A751/pBC38C or an oral buffer. All animals vaccinated with 1A751/CTB-TEpiAs developed specific anti-FMDV IgA in lung and gut lavage fluid, serum ELISA antibody, neutralizing antibody as well as T lymphocyte proliferation, and IFN-γ secretory responses. Three of the five guinea pigs vaccinated with 1A751/CTB-TEpiAs were protected completely from the viral challenge. The results demonstrate the potential viability of a B. subtilis-based recombinant vaccine for the control and prevention of FMDV infections.